Standout Papers

Intensive versus Moderate Lipid Lowering with Statins after Acute Cor... 1996 2026 2006 2016 3.4k
  1. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes (2004)
    Christopher P. Cannon, Eugene Braunwald et al. New England Journal of Medicine
  2. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes (2013)
    William B. White, Christopher P. Cannon et al. New England Journal of Medicine
  3. C-Reactive Protein Levels and Outcomes after Statin Therapy (2005)
    Paul M. Ridker, Christopher P. Cannon et al. New England Journal of Medicine
  4. TIMI Frame Count (1996)
    C. Michael Gibson, Christopher P. Cannon et al. Circulation
  5. Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban (2001)
    Christopher P. Cannon, William S. Weintraub et al. New England Journal of Medicine
  6. Cardiac-Specific Troponin I Levels to Predict the Risk of Mortality in Patients with Acute Coronary Syndromes (1996)
    Elliott M. Antman, Milenko J. Tanasijevic et al. New England Journal of Medicine
  7. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (2020)
    Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine
  8. Acute myocardial infarction (2016)
    Grant W. Reed, Jeffrey Rossi et al. The Lancet
  9. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes (2020)
    Christopher P. Cannon, Richard E. Pratley et al. New England Journal of Medicine
  10. The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes (2001)
    James A. de Lemos, David A. Morrow et al. New England Journal of Medicine
  11. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (2017)
    Christopher P. Cannon, Deepak L. Bhatt et al. New England Journal of Medicine
  12. Clopidogrel with or without Omeprazole in Coronary Artery Disease (2010)
    Deepak L. Bhatt, Byron Cryer et al. New England Journal of Medicine
  13. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease (2020)
    Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine
  14. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes (2020)
    Darren K. McGuire, Weichung Shih et al. JAMA Cardiology
  15. Relationship of TIMI Myocardial Perfusion Grade to Mortality After Administration of Thrombolytic Drugs (2000)
    C. Michael Gibson, Christopher P. Cannon et al. Circulation
  16. C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy (1998)
    David A. Morrow, Nader Rifai et al. Journal of the American College of Cardiology
  17. Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction (2012)
    Benjamin A. Steinberg, Xin Zhao et al. Circulation
  18. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial (2015)
    Faı̈ez Zannad, Christopher P. Cannon et al. The Lancet
  19. Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes (2002)
    Marc S. Sabatine, David A. Morrow et al. Circulation
  20. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease (2010)
    Christopher P. Cannon, Sukrut Shah et al. New England Journal of Medicine
  21. Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy (2006)
    Christopher P. Cannon, Benjamin A. Steinberg et al. Journal of the American College of Cardiology
  22. Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease (2007)
    Clive Rosendorff, Henry R. Black et al. Circulation
  23. Diabetes and Mortality Following Acute Coronary Syndromes (2007)
    Sean M. Donahoe, Garrick C. Stewart et al. JAMA
  24. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials (2015)
    Jessica L. Mega, Nathan O. Stitziel et al. The Lancet
  25. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study (2010)
    Christopher P. Cannon, Robert A. Harrington et al. The Lancet
  26. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes (2015)
    Robert Ćhilton, I. Tikkanen et al. Diabetes Obesity and Metabolism
  27. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial (2015)
    Patrick M. Moriarty, Paul D. Thompson et al. Journal of clinical lipidology
  28. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial (2015)
    Christopher P. Cannon, Bertrand Cariou et al. European Heart Journal
  29. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study (2015)
    Dean J. Kereiakes, Jennifer G. Robinson et al. American Heart Journal
  30. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial (2019)
    David Fitchett, Silvio E. Inzucchi et al. Circulation

Immediate Impact

5 from Science/Nature 151 standout
Sub-graph 1 of 17

Citing Papers

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
2020 Standout
37 intermediate papers

Works of Christopher P. Cannon being referenced

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
2020 Standout
Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients
2013
and 21 more

Author Peers

Author Last Decade Papers Cites
Christopher P. Cannon 37120 27182 13675 869 65.6k
Eugene Braunwald 49596 29906 12024 687 75.0k
Marc A. Pfeffer 62884 25888 17255 593 94.5k
Marc S. Sabatine 27026 22026 12790 499 49.0k
Philippe Gabríel Steg 54884 29325 9558 1.1k 74.8k
Donald M. Lloyd‐Jones 33587 17512 11336 716 66.3k
Peter W.F. Wilson 34252 30320 29024 632 107.0k
Emelia J. Benjamin 68687 11568 8206 766 98.8k
Eugene Braunwald 41820 18050 4791 444 56.1k
Martin G. Larson 51911 12342 9351 580 86.7k
Aaron R. Folsom 26297 10864 10042 859 73.5k

All Works

Loading papers...

Rankless by CCL
2026